<DOC>
	<DOCNO>NCT00655668</DOCNO>
	<brief_summary>This Phase II , multicenter , single-arm , open-label study oral lenalidomide monotherapy administer subject relapse refractory T-cell lymphoma . This study conduct two phase : Treatment Phase Follow-up Phase . Subjects qualify enrollment study enter Treatment Phase receive single-agent lenalidomide 25 mg daily Days 1-21 every 28 day ( 28-day cycle ) . Subjects may continue participation Treatment Phase study maximum duration 24 month , disease progression unacceptable adverse event develop . All subject discontinue Treatment Phase reason continue follow progression disease next lymphoma treatment give , whichever come first , Follow-up Phase . Objectives : Primary : • To determine efficacy lenalidomide monotherapy relapse refractory T-cell Non-Hodgkin 's Lymphoma ( NHL ) . Efficacy assess measure response rate , tumor control rate , duration response , time progression progression free survival . Secondary : • To evaluate safety lenalidomide monotherapy treatment subject relapse refractory T-cell NHL .</brief_summary>
	<brief_title>A Phase II Study Single-Agent Lenalidomide Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Study terminate . Study data assessment reveal study drug active , likely sufficiently active single agent population registration purpose .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Must ≥ 18 year age time sign informed consent form . Must able adhere study visit schedule protocol requirement . Biopsyproven Tcell NonHodgkin 's Lymphoma , either : Peripheral Tcell Lymphoma ( PTCL ) whatever subtype , Cutaneous Tcell Lymphoma ( CTCL ) , subtype mycosis fungoides . Relapsed refractory previous therapy Tcell NonHodgkin 's Lymphoma . Must receive least one prior combination chemotherapy regimen . There limit number prior therapy . Cutaneous Tcell Lymphoma subtype Sézary Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NHL , Non-Hodgkin 's Lymphoma , T-cell Lymphoma</keyword>
</DOC>